Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 21 of 21
Plenary Session 3: Targeting DNA Repair, PARP, and Beyond
Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response
Daniel Durocher
Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 8:00 AM-9:45 AM
Plenary Session 4: The Role of Liquid Biopsies in Guiding Cancer Therapeutics-- Detection, Response Monitoring, and Resistance
Background and use of circulating tumor-derived DNA and circulating tumor cells as biomarkers
Martijn Lolkema
Erasmus MC, Rotterdam, Netherlands
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 10:00 AM-11:45 AM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen
Mirati Therapeutics, San Diego, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors
Pasi A Jänne
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Plenary Session 3: Targeting DNA Repair, PARP, and Beyond
Targeting DNA Repair and Defective DNA repair
Johann de Bono
The Institute of Cancer Research and Royal Marsden, London, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 8:00 AM-9:45 AM
Plenary Session 3: Targeting DNA Repair, PARP, and Beyond
Exploiting DNA replication stress for cancer therapies
Thanos Halazonetis
University of Geneva, Geneva, Switzerland
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 8:00 AM-9:45 AM
Plenary Session 4: The Role of Liquid Biopsies in Guiding Cancer Therapeutics-- Detection, Response Monitoring, and Resistance
  •  
  • Free
  • Coming soon
  • Some slides withheld
  •  
  •  
Extracellular vesicles as opportunities for integrative or focused liquid biopsy studies
Jennifer Jones
National Cancer Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 10:00 AM-11:45 AM
Plenary Session 4: The Role of Liquid Biopsies in Guiding Cancer Therapeutics-- Detection, Response Monitoring, and Resistance
Clinical implications of serial analysis of circulating tumor DNA in patients with stages I to III colorectal cancer
Claus L. Andersen
Aarhus University Hospital, Aarhus, Denmark
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 10:00 AM-11:45 AM
Spotlight on Proffered Papers 2
  •  
  • Free
  • Coming soon
  • Some slides withheld
  •  
  •  
The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies
Sonia Iyer
Whitehead Institute for Biomedical Research, Cambridge, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 11:50 AM-12:20 PM
Spotlight on Proffered Papers 2
  •  
  • Permission not
    granted for presentation
  •  
  •  
Development of new immune therapy combinations for ovarian cancer using genetically defined organoid platform
Shuang Zhang
NYU Langone Health, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 11:50 AM-12:20 PM
Spotlight on Proffered Papers 2
PET imaging of biomarkers in immuno-oncology for response prediction and treatment monitoring
Carsten H. Nielsen
Minerva Imaging, Copenhagen, Denmark
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 11:50 AM-12:20 PM
Concurrent Session 4: Targeting the Innate Immune System
Integrating anti-GD2 therapies and fusokines with NK cells for pediatric solid tumors
Christian M Capitini
University of Wisconsin, Madison, WI, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 4: Targeting the Innate Immune System
  •  
  • Permission not
    granted for presentation
  •  
  •  
Genetically Engineered Natural Killer Cell Lines For Treatment of Cancer
Hans Klingemann
NantKwest, Inc., Woburn, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 4: Targeting the Innate Immune System
Exploring Approaches to Optimize NK Cell-Based Immunotherapy for Cancer
Richard W Childs
National Heart, Lung, and Blood Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
Chairperson
Ruth Plummer
Northern Institute for Cancer Research, Newcastle, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
Next generation strategies to overcome adaptive resistance to MAPK-directed therapies
Poulikos Poulikakos
Icahn School of Medicine at Mount Sinai, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Benjamin Bader
Bayer AG, Berlin, Germany
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 5: Targeting the RAS/MAP Kinase Pathway
  •  
  • Permission not
    granted for presentation
  •  
  •  
Therapeutic response and resistance to pan-RAF inhibition: From bench to clinic and back
Shiva Malek
Genentech, Inc., South San Francisco, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 6: The Genomic Landscape of Cancer and the Evolution of Tumor Heterogeneity
Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer
Himisha Beltran
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 6: The Genomic Landscape of Cancer and the Evolution of Tumor Heterogeneity
  •  
  • Permission not
    granted for presentation
  •  
  •  
Therapeutic optimization driven by evolutionary fitness mapping and ultra-sensitive liquid biopsy
Dan Landau
Weill Cornell Medicine, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
Concurrent Session 6: The Genomic Landscape of Cancer and the Evolution of Tumor Heterogeneity
  •  
  • Permission not
    granted for presentation
  •  
  •  
Lung cancer evolutionary trajectories and immune escape
Nicholas McGranahan
University College London, London, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 21 of 21